Control of viral replication after cessation of HAART - Wikidata - awgldk - TriplyDB

Control of viral replication after cessation of HAART

Control of viral replication after cessation of HAART

http://www.wikidata.org/entity/Q34615847

about

Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients.HIV-1 transcription and latency: an update.Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy.

P2860

Q26865388-24F9C407-1A24-4851-BF47-FC73A6825CA4 Q34292622-EC429191-BE17-48D9-A9BA-4E9CE0742242 Q36976156-0BCD5DB5-D824-4C55-842A-27178AAAB832 Q40250340-2D268005-7943-4009-AFE2-1EF4C8611458

P2860

Control of viral replication after cessation of HAART

http://www.wikidata.org/entity/Q34615847

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Control of viral replication after cessation of HAART

@ast

Control of viral replication after cessation of HAART

@en

Control of viral replication after cessation of HAART

@nl

type

label

Control of viral replication after cessation of HAART

@ast

Control of viral replication after cessation of HAART

@en

Control of viral replication after cessation of HAART

@nl

prefLabel

Control of viral replication after cessation of HAART

@ast

Control of viral replication after cessation of HAART

@en

Control of viral replication after cessation of HAART

@nl

P1433

Q34615847-0B7B40E1-308C-4DC5-8231-5A98183628E8

P1476

Q34615847-09F0A037-0550-48A0-AE0E-02F3402919CD

P2093

Q34615847-1AE4F6EF-C26D-4A4A-A7E4-79810C772A65

Q34615847-2A69C947-5B5E-4EBB-B87D-D8FC0FD384AE

Q34615847-2B091BAB-A125-4994-A218-EF4B906E49AC

Q34615847-3DEC2228-FB55-45D3-AD5C-66B520F8D951

Q34615847-90C93635-6DC9-4EBC-84E8-9ACAF114E599

Q34615847-955716DD-546C-4634-924B-601AD34E0F86

Q34615847-FD8E43B0-4FF6-475C-8A89-96410C3BB551

P2860

Q34615847-04060A87-2494-4564-BF45-EDD7BD36E744

Q34615847-26BE7B96-7FF6-401C-86F4-CC27873D2005

Q34615847-29F90D91-6F00-43E8-AF7F-C66383591522

Q34615847-2A20C44B-C08D-49C9-A533-246807041506

Q34615847-2E4E1196-4340-465D-AF08-DE9022FF46C1

Q34615847-62D5D0EC-EA33-4283-8D5D-95475803AC4B

Q34615847-65171D16-87A4-4A97-BFEA-B8720B1AD53A

Q34615847-6A882817-C33C-46EB-AB01-DD4963F5F209

Q34615847-6F6184DB-1E26-476E-9554-065072E942A3

Q34615847-8B15D96C-69C8-4A7D-9D68-F7E8C3CA07BF

P2888

Q34615847-69D16F05-B5B1-4196-A966-736970A37B16

P304

Q34615847-13C4C133-45F6-4038-BC47-A592287B9987

P31

Q34615847-83DF59BC-7046-4C9E-83F9-0095DD13210B

P356

Q34615847-09D6B256-06B1-44A3-B48F-DFC749CE7F79

P433

Q34615847-6661FAB3-5887-4DED-B983-92E9DEA84AA5

P478

Q34615847-E1074222-43B5-4A55-A155-AB281AAC3DCC

P50

Q34615847-2CC3B276-998A-4B4F-983B-BABD2C2680E4

P577

Q34615847-95782779-6379-4669-AD68-5134582DA449

P5875

Q34615847-BFA6826C-B1EE-47DC-A0EC-7C0DCEAA1F3D

P6179

Q34615847-F785F8C3-4ED6-4742-838C-60C519DE1B57

P698

Q34615847-03FDC854-F15C-4FA5-9D47-747E7FE8D1DE

P932

Q34615847-E8760376-45D8-497E-A621-50121A803E09

P356

P1433

AIDS Research and Therapy

P1476

Control of viral replication after cessation of HAART

@en

P2093

Anne Buvé

http://www.w3.org/2001/XMLSchema#string

Ellen Van Gulck

http://www.w3.org/2001/XMLSchema#string

Guido Vanham

http://www.w3.org/2001/XMLSchema#string

Leo Heyndrickx

http://www.w3.org/2001/XMLSchema#string

Lotte Bracke

http://www.w3.org/2001/XMLSchema#string

Paul Lewi

http://www.w3.org/2001/XMLSchema#string

Sandra Coppens

http://www.w3.org/2001/XMLSchema#string

P2860

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression.

Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations

Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

Evaluation of HIV-1 p24 antigenemia and level of CD8+CD38+ T cells as surrogate markers of HIV-1 RNA viral load in HIV-1-infected patients in Dakar, Senegal.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements.

Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals.

P2888

P304

6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1742-6405-8-6

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49830070

http://www.w3.org/2001/XMLSchema#string

P6179

1052571377

http://www.w3.org/2001/XMLSchema#string

P698

21314914

http://www.w3.org/2001/XMLSchema#string

P932

3046910

http://www.w3.org/2001/XMLSchema#string